Pyridoxine-dependent epilepsy: an under-recognised cause of intractable seizures

Nune S Yeghiazaryan1, Federico Zara, Giuseppe Capovilla

  • 1Armenian Republican Epilepsy Centre Erebouni, Yerevan State Medical University, Yerevan, Armenia. ynune@yahoo.com

Insights

Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder causing severe infant seizures. Early pyridoxine treatment is crucial for managing this condition, even when other therapies fail.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder.
  • It causes intractable seizures in neonates and infants, often resistant to standard anti-epileptic drugs.

Observation:

  • Patients with PDE typically respond well to pyridoxine administration.
  • Seizure types vary, with status epilepticus being common.
  • Electroencephalographic and neuroimaging findings are not specific for PDE.

Findings:

  • Elevated urinary α-aminoadipic semialdehyde is a reliable biomarker for PDE.
  • Mutations in the ALDH7A1 gene are found in most PDE patients.
  • ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase.

Implications:

  • Early consideration of a pyridoxine trial is paramount for infants with intractable early-onset seizures.
  • Identifying PDE is critical for appropriate and timely treatment.
  • Intellectual disability is a frequent long-term outcome if not treated promptly.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...